90 results about "KRAS Gene Mutation" patented technology

The invention relates to the field of molecular biology and aims to provide an ARMS-qPCR (Allele Refractory Mutation System-quantitative Polymerase Chain Reaction) detection kit for KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) gene mutation subtype and a detection method. The kit comprises a qPCR hybrid reaction solution, a locked nucleic acid retardant probe, a reference primer, an ARMS primer and a positive control sample, wherein the qPCR hybrid reaction solution comprises a PCR buffer solution, dNTPs (Deoxynucleotide Triphosphates), MgCl2, GoldStarbest Taq enzyme, a universal PCR reverse primer and a universal TaqMan probe. The kit provided by the invention can be used for rapidly and accurately detecting specific locus mutation of KRAS genes in various cancer tissues with high sensitivity, has high sensitivity, and can be used for detecting genome DNA with various tissue origins, specially free DNA segments adopting cell-free systems, such as blood serum and blood plasma, orother body fluid origins, wherein the genome DNA is derived from cell systems. Compared with direct sequencing and other mutation detection technologies, the kit and the detection method thereof havethe advantages of strong specificity, high sensitivity, simplicity and rapidness in operation, high throughput, safety, definiteness and objectivity in result identification and the like for detecting the KRAS gene mutation.

The invention provides a kit for early stage colorectal cancer auxiliary diagnosis and a use method and a detection system thereof. The kit comprises a nucleic acid isolation and purification reagent, a DNA (deoxyribonucleic acid) sulfite conversion reagent, a KRAS (kirsten rat sarcoma viral oncogene homolog) gene mutation detection reagent, a BMP3 (bone morphogenetic protein 3) and NDRG4 (N-myc downsteam regulated gene 4) gene methylation detection reagent and a fecal occult blood detection reagent, wherein the nucleic acid isolation and purification reagent is used for separating and purifying the human DNA in a faeces sample; the DNA sulfite conversion reagent is used for performing sulfite conversion on the purified partial human DNA, and is used for subsequent BMP3 and NDRG4 gene methylation detection. Through detecting two kinds of indexes of DNA and fecal occult blood in the faeces sample in a combined way, the kit provided by the invention is used for the early stage screening of the colorectal cancer. Compared with an FOBT (fecal occult blood test) detection method, the kit provided by the method can realize higher sensitivity on the detection of colorectal cancer, particularly the developing period tumor.

The present invention discloses primers, probes, a detection system and a kit for one time detection of lung cancer multiple genes, wherein the primers, the probes, and the distribution way for detecting 25 EGFR gene mutations, 7 KRAS gene mutations, 6 BRAF gene mutations, 9 NRAS gene mutations, 5 HER2 gene mutations, 2 PIK3CA gene mutations, 5 fusion genes of ALK5, 13 fusion genes of ROS1, and 6 fusion genes of RET are provided. According to the present invention, the detection kit adopts the 12 linking PCR reaction strip design, each 12 linking PCR strip detects multiple genes of a sample, and the corresponding fusion detection reagents and the internal control reagents are filled in the pipes 1-4 of the 12 linking PCR strip; and with the primers, the probes, the detection system and the kit, the one-time detection of the 24 fusions and the 54 mutations of the lung cancer can be achieved, such that the detection time is substantially shortened, the sensitivity is high, the specificity is strong, the operation is simple and rapid, and the reference for selection of tumor targeting drug therapy on lung cancer patients can be provided for clinician.

The invention discloses a spiro-substituted pyrimido-cyclic compound with selective inhibition effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound or a prodrug thereof; the spiro-substituted pyrimido-cyclic compound is represented by a formula (I), and the definition of each group or symbol in the formula is shown in the specification in detail.In addition, the invention also discloses a pharmaceutical composition containing the compound and an application of the compound in preparation of cancer drugs.

The present invention discloses a T cell receptor, which specifically binds to a KRAS gene codon 12 mutation G12D 26aa peptide, wherein the amino acid sequence of the peptide is represented by SEQ IDNO:1 MTEYKLVVVGADGVGKSALTIQLIQN, the 9-12aa epitope polypeptide with high affinity is represented by SEQ ID NO:48 VVVGADGVGK and SEQ ID NO:49 KLVVVGADGVGK when the T cell receptor can identify the HLAmolecule antigen complex, and the HLA molecule is HLA-A0301. The invention discloses the amino acid sequences of the alpha chain and the beta chain of the T cell receptor in the identification of theantigen complex formed by the KRAS gene G12D mutation peptide and the HLA-A0301, nucleotide sequences encoding the alpha chain and the beta chain of the T cell receptor, a vector containing the nucleotide sequences, cells containing the nucleotide sequences, and applications of the vector or the cells in preparation of drugs for prevention and treatment of diseases related to KRAS gene mutation.

The invention discloses a PCR (Polymerase Chain Reaction) reaction kit for detecting KRAS (Kirsten Rat Sarcoma) gene mutation, which is characterized by comprising a plurality of primer pairs used for specifically amplifying a targeting sequence of the KRAS gene, and each primer pair contains a continuous nucleotide sequence formed by at least 15 continuous nucleotides in a second exon KRAS2 or athird exon KRAS 3 of the KRAS gene, wherein the KRAS2 has the continuous nucleotide sequence of SEQ ID No:1, and the KRAS3 has the continuous nucleotide sequence of the SEQ ID No: 2. The kit completes the judgment on a genotype sample by adopting a saturated probe and a high resolution fusion curve analysis technology so as to provide guidance on medicine selection and diagnosis for various tumors including lung cancers and colorectal cancers.

The invention discloses a substituted heteroaromatic ring dihydropyrimidinone derivative with selective inhibition effect on KRAS gene mutation or a pharmaceutically acceptable salt, a stereoisomer, asolvate or a prodrug thereof. The substituted heteroaromatic ring dihydropyrimidinone derivative is shown as a formula (I), and each group in the formula is as defined in the specification. In addition, the invention also discloses a pharmaceutical composition containing the compound and application of the compound in preparation of cancer drugs.

The invention provides a method for rapidly detecting the mutation of KRAS gene, to overcome the disadvantages of low sensitivity and inaccuracy in conventional probe melting curve assay. The method for rapidly detecting the mutation of KRAS gene comprises the following steps: (1) designing and synthesizing molecular beacon probe and template amplification primers; (2) extracting the KRAS genome DNA of a detected sample; (3) preparing a reaction system; (4) performing PCR reaction; performing melting curve analysis after the PCR reaction is finished, and determining if a KRAS mutation occurs in the detected sample through the Tm value of a melting peak. The method combines the molecular beacon probe and extension retardance primers, and uses the DNA polymerase without 5'->3' exonuclease activity to detect KRAS mutation rapidly in vitro, thereby saving consumables simultaneously having the characteristics of high sensitivity and specificity which ensure a more reliable detection result.

The invention relates to a test method of KRAS gene mutation for screening and assessing therapeutic effects of molecular targeted agents, which is characterized by the following specific steps: acquiring serum or tumor tissue samples of testees, extracting genomic DNA, testing a No.2 exon of the KRAS gene, designing corresponding site-specific primers and adopting experimental schemes, reagents and report generation systems for sequence determination and assessing the effectiveness of EGFR tyrosine kinase inhibitors used for treating cancer individuals by simultaneously testing and analyzingwhether mutation exists on the No.2 exon of the individual KRAS gene. The method has the advantage of being used for application of the EGFR tyrosine kinase inhibitors used for treating cancer individuals.

The invention provides a method for performing in-vitro accurate test on KRAS gene mutation, and the method is used for overcoming the defects that the conventional allele-specific polymerase chain reaction (PCR) method has insufficient specificity and false positive phenomenon. The method for performing the in-vitro accurate test on the KRAS gene mutation comprises the following steps of: (1) designing and synthetizing allele specific primers which comprise the allele specific primers espectively designed for 7 types of mutation of a typical KRAS gene exon 2 and are utilized as forward primers, wherein extension retardant primers are utilized as common downstream primers; (2) extracting the KRAS genomic deoxyribose nucleic acid (DNA) of a test sample, and additionally preparing the wild type genomic DNA (as wild type template); and (3) carrying out the real-time fluorescent PCR reaction. The test method has the advantages of strong specificity, high sensitivity, material conservation and time-saving property.

The invention relates to the technical field of gene detection, in particular to an LNA (Locked Nucleic Acid) probe, which is represented by sequences 1, 2, and 3 in a sequence table, for detecting KRAS gene mutation. A detection method for the KRAS gene mutation comprises the following steps: constructing a nanopore sensor by natural alpha-hemolysin, hybridizing the LNA probe with a gene to be detected to obtain a hybrid material, and generating a blocking signal through a nano channel of the nanopore sensor. By the hybridization of the LNA-modified probe and a KRAS mutant gene and detection of the alpha-hemolysin nanopore sensor, the specificity of target gene detection is greatly improved, and a concentration relation between the frequency of the signal and the KRAS mutant gene can be constructed to quantitatively analyze a target; the LNA probe has the advantages of simplicity, quickness and high sensitivity; DNA amplification is not needed; the operation is simple and specific; the LNA probe is high in applicability.

The invention belongs to the technical field of biology and particularly relates to a human multi-gene mutation detection kit based on a high-throughput sequencing method and an application thereof. The kit includes a KRAS gene mutation detection primer pair, an EGFR gene mutation detection primer pair and an ALK gene fusion detection primer pair. The kit can simultaneously detect DNA mutation and RNA fusion, is high in sensitivity and low in detection limit, is high in specificity, has good repeatability, and can reach 100% in both accuracy and positive coincident rate.

The invention discloses a KRAS gene mutation detection quantification standard product as well as a preparation method and a valuing method thereof. The preparation method comprises the following steps: performing PCR (Polymerase Chain Reaction) amplification by taking seven common mutant cell line DNAs (Deoxyribonucleic Acids) containing KRAS genes as a template to obtain a PCR product, and performing Sanger sequencing verification; mixing the PCR product with wild type human genome DNAs being subjected to ultrasonic fragmentation according to a certain proportion through balance weighing toobtain a quantification standard product for seven mutations of a KRAS gene. The invention provides a preparation method of a quantification standard product. Fragmented wild type human genome DNAs are taken as background DNAs, so that the background of an actual detection sample can be better simulated. A valuing method of the quantification standard product has high precision and high accuracy,and is independent of a DNA standard product; a measurement result can be traced to the international basic unit (mass), so that the reliability and traceability of the measurement result are ensured.The quantification standard product can be applied to method verification and quality control of a KRAS gene mutation detection method.

The invention relates to the field of gene engineering and molecular biology, and provides a KRAS gene mutation detection method and a kit. The method comprises the following steps: A, amplifying a target region in a to-be-sequenced sample by using a KRAS specific primer to obtain an amplification product, wherein at least one PCR (Polymerase Chain Reaction) primer in the KRAS specific primer for amplifying each target region comprises a breakable site or a cuttable sequence; B, adding the amplification product into a cutting-connection reaction system to perform cutting and connection so as to connect a joint I and a joint II to the two ends of the amplification products to obtain library molecules; C, performing monomolecular amplification on the library molecules comprising the joint I and the joint II to obtain a monomolecular amplification product; D, performing high-throughput sequencing on the monomolecular amplification product to obtain sequence information on the target region. According to the method and the kit, the experiment steps can be simplified and the detection efficiency is improved.

The invention relates to a primer probe for detecting mutation of a KRAS gene and a kit thereof. The kit comprises digital PCR (polymerase chain reaction) premix liquid, a liquid droplet stabilizer and primer probe mixing liquid, wherein the digital PCR premix liquid is used for preparing digital PCR reaction liquid; the primer probe mixing liquid comprises upstream and downstream primers A for detecting a 12th codon, a mutation probe A for a G12R site of the 12th codon, a mutation probe B for a G12V site of the 12th codon, a mutation probe C for a G12D site of the 12th codon, a mutation probe D for a G12A site of the 12th codon, a mutation probe E for a G12S site of the 12th codon, and a mutation probe F for a G12C site of the 12th codon; upstream and downstream primers B for detecting a 13th codon, and a mutation probe G for a G13D site of the 13th codon; upstream and downstream primers C for detecting a 61st codon, and a mutation probe H for a Q61L site of the 61st codon. The kit for detecting the mutation of the KRAS gene has the advantages that the sensitivity and specificity are high, the sample demand amount is small, and multiplex PCR detection can be rapidly and accurately performed.

The invention discloses a colorectal cancer auxiliary diagnosis kit for fecal nucleic acid detection and a use method of the colorectal cancer auxiliary diagnosis kit. The kit comprises a KRAS gene mutation detection reagent, a fusobacterium nucleatum detection reagent, a DNA sulfite conversion reagent and a Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection reagent. The use method comprises the following steps: collecting an excrement sample, and then completing DNA purification, KRAS gene mutation detection, fusobacterium nucleatum abundance detection and Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection of the sample by using reagents in the kit; and calculating the obtained data through a logistic regression model, and performing result evaluation and analysis. The colorectal cancer detection sensitivity reaches 89% or above, the specificity reaches 94% or so, high-sensitivity and high-specificity colorectal cancer detection can be achieved, and doctors can be helped to guide follow-up treatment medication of patients.

This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient,

the method comprising:

• • (1) detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient; and
  • (2) predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1).

The invention relates to methods of treating lung cancer using glutaminase inhibitors. In particular, results demonstrate that lung cancers characterized by an EGFR or KRAS mutation are treated by glutaminase inhibitors.

The invention provides a primer and probe for detecting mutant KRAS genes and further provides a method and kit for detecting mutant KRAS genes by using the primer and the probe. By adopting the primer and probe provided by the invention, the amplification of wild KRAS genes can be inhibited, and the combination of the wild KRAS genes with the probe can be also inhibited, thus less than 1% of mutant KRAS genes can be detected.

The invention belongs to the field of biotechnology and discloses a kit for detecting the hotspot mutation of KRAS gene and a detection method thereof. The kit comprises a PNA (peptide nucleic acid) reagent; and the wild type KRAS gene sequence is closed by a clamp technology so as to improve the sensitivity of a sanger sequencing process and the detection rate of the KRAS gene mutation. The detection method disclosed by the invention is simple and safe to operate and does not need many expensive reagents, thereby being economical and efficient; and meanwhile, the detection method also has the advantage of short operation time, and the whole detection process is finished within 4-6 hours.

The invention provides a detection method of KRAS gene mutation and a kit. The detection method comprises the following steps of: (a) extracting DNA in the sample, and carrying out PCR amplification by using specific primers under specified conditions; and (b) and sequencing the amplified products, comparing with normal KRAS gene, and determining whether gene mutation exists. The specific primers are 2-4 pairs of primers aiming at different exons of the KRAS gene. By adopting the detection method and the kit of the invention, the detection speed can be improved and the reagent and time are saved. By utilizing the detection result, the administration for clinical chemotherapy of alimentary tract tumors can be guided.

The invention discloses a kit for detection of human KRAS gene mutations. The kit comprises specific primer pairs of seven genes and seven probe primers cooperatively used with the specific primers. Mixed liquid of primers and probes includes mutation site genes and internal-control primer probes, quality control genes and internal-control detection primer probes, FAM fluorescein used for labeling mutation and quality control probes and an internal control marker HEX fluorescein; quality control and internal control are taken into consideration in result interpretation; the quality control genes are selected from the conserved segment of the human KRAS gene, and the conserved human beta-actin gene is used as internal control; and a double-control system is employed for monitoring the mass of DNA and PCR reaction process in blood plasma samples. Compared with the prior art, the invention has the following beneficial effects: 1) the method has high sensitivity and can detect 1% trace mutation templates under the background of 100 ng of wild mankind genomes, so false negative results are reduced; 2) a totally-enclosed reaction is carried out to avoid false positive results; and 3) the double-control reaction system is employed, so PCR amplification and nucleic acid extraction are effectively detected via quality control and internal control.

The invention discloses a tetrahydropyrido[3,4-d]pyrimidine-2-(1H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salt, stereoisomer, solventcompound or prodrug thereof, the compound is shown as a formula I, and the definition of each group in the formula is shown in the specification in detail. In addition, the invention also discloses apharmaceutical composition containing the compound and application of the compound in preparation of cancer drugs.